Possible effects of tetrahydrobiopterin treatment in six children with autism ‐ clinical and positron emission tomography data: a pilot study

@article{Fernell1997PossibleEO,
  title={Possible effects of tetrahydrobiopterin treatment in six children with autism ‐ clinical and positron emission tomography data: a pilot study},
  author={Elisabeth Fernell and Yasuyoshi Watanabe and Ingrid Adolfsson and Yoshihiro Tani and Mats Bergstr{\"o}m and Per Hartvig PhD and Anders Lilja Md and Anne‐Liis von Knorring MD. PhD. and Christopher Gillberg MD. PhD. and Bengt L{\'a}ngstr{\"o}m PhD.},
  journal={Developmental Medicine \& Child Neurology},
  year={1997},
  volume={39}
}
Six children, between 3 and 5 years of age, having infantile autism according to DSM‐III‐R, were treated for 3 months with 6R‐L‐erythro‐5,6,7,8‐tetrahydrobiopterin (R‐BH4), a cofactor for tyrosine hydroxylases in the biosynthetic pathway of catecholamines and serotonin. A criterion for inclusion in the study was a relatively low level of R‐BH4 in the cerebrospinal fluid. For clinical evaluation, the Parental Satisfaction Survey (PASS) was used every fourth week and the Griffiths Developmental… Expand
Tetrahydrobiopterin in the Treatment of Children With Autistic Disorder: A Double-blind Placebo-Controlled Crossover Study
TLDR
Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment. Expand
Administration of secretin for autism alters dopamine metabolism in the central nervous system
TLDR
Findings suggest that secretin activated metabolic turnover of dopamine in the central nervous system via BH(4), improving symptoms. Expand
Tetrahydrobiopterin as a novel therapeutic intervention for autism
TLDR
BH4 represents a novel therapy for ASD, one that may gain wider use after further clinical studies have established efficacy and treatment guidelines and the evidence for a therapeutic benefit of BH4 treatment in children with ASD is concluded. Expand
Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial.
TLDR
Results indicate that BH4 offers promise in reducing symptoms of ASD, and no differences were found on global improvement as measured with the CGI-I or CGI-S. Expand
Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study
TLDR
Behavioral improvement associated with daily 20 mg kg−1 sapropterin treatment may involve NO metabolism, particularly the status of pretreatment NO metabolism. Expand
Tetrahydrobiopterin Deficiency in Autism Spectrum Disorder
TLDR
This case series suggests that children with ASD can have a CNS deficiency in tetrahydrobiopterin and that this deficiency is most likely secondary to reduced precursor availability, reduced recycling and/ or increased utilization due to other multifactorial abnormalities associated with ASD such as abnormalities in CNS folate and/or oxidative stress. Expand
Comparison of Three Clinical Trial Treatments for Autism Spectrum Disorder Through Multivariate Analysis of Changes in Metabolic Profiles and Adaptive Behavior
TLDR
Results are suggestive of an ability to effectively improve pathway-wide FOCM/TS metabolic and behavioral abnormalities in ASD with clinical treatment. Expand
An approach to the nutritional management of autism.
  • P. Kidd
  • Medicine
  • Alternative therapies in health and medicine
  • 2003
TLDR
Kanner’s “c l a s s i c” autism, termed autistic disorder or AD, is now included with the other autistic disorders into the cat e g o ry autistic spectrum disorder or (ASD), less commonly termed Pervasive Developmental D i s o rders (PDD). Expand
Central Tetrahydrobiopterin Concentration in Neurodevelopmental Disorders
  • R. Frye
  • Medicine
  • Front. Neurosci.
  • 2010
TLDR
The relationship between cerebrospinal fluid BH4 concentration and serum amino acids was studied, and data suggests that central BH 4 concentration may be related to systemic inflammation and oxidative stress pathways. Expand
Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain.
TLDR
It is hypothesize that a comprehensive, biologically oriented approach to the use of psychotropics in the regulation of neurotransmission during pre- and postpartum periods may result in better outcomes in this population of women. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients
TLDR
The results suggest that the endogenous biosynthesis of R-BH4 in the brain may be reduced in autistic children as compared with that in neurologically normal children. Expand
Plasma and urinary levels of biopterin, neopterin, and related pterins and plasma levels of folate in infantile autism
TLDR
Assessment of plasma and urinary levels of tetrahydrobiopterin in infantile autism and the status of neopterin and monapterin in these individuals indicated that no simple explanation for the beneficial effects of administration of tetrahedralopterin on autistic children can be offered at the present time. Expand
Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. CSF homovanillic acid and 5-hydroxyindoleacetic acid.
TLDR
There were no significant differences in metabolite concentrations among autistic, nonautistic psychotic, aphasic, and cognitively and attentionally impaired groups, or between the developmentally disabled and contrast groups of children. Expand
CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood.
Spinal fluid concentrations of the three major monoamine metabolites were examined in 25 infantile autistic children and 12 children with other childhood psychoses, and were contrasted with resultsExpand
Fenfluramine treatment of twenty children with autism
TLDR
Serotonin decreased 53% after fenfluramine treatment and rebounded to a level 35% higher than baseline following a placebo period and any correlation between good clinical response and low baseline serotonin levels or high baseline IQ was not found. Expand
Effects of vitamin B6 on averaged evoked potentials in infantile autism.
TLDR
During treatment of the autistic children with B6, an increase of amplitude of middle-latency evoked potentials and a decrease of urinary homovanillic acid were found and the reverse was noted in the normal subjects. Expand
Urinary free and conjugated catecholamines and metabolites in autistic children
TLDR
Results suggest that autistic behaviour might be related to an abnormal functional imbalance among monoamines either at a molecular level or at a system level and emphasize the special interest of urinary assays in pediatric research. Expand
Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
TLDR
In 1966, when an outpatient treatment program for autistic children and their families was initiated, there were two major sets of guidelines for diagnosing the children who were referred to the program, and the most promising at tempt to translate the Kanner definition into an empirical rating scale was the Rimland Checklist. Expand
Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.
In this double-blind, placebo-controlled study the administration of haloperidol resulted in significant decreases in behavioral symptoms and in general clinical improvement in 40 autistic childrenExpand
The cognitive profile in infantile autism--a study of 70 children and adolescents using the Griffiths Mental Development Scale.
TLDR
A characteristic profile emerged with peaks in motor and visuo-spatial domains and troughs in verbal and practical reasoning areas in children and adolescents with infantile autism tested with the Griffiths Mental Development Scale II. Expand
...
1
2
...